{
  "docId": "019de516-9989-7672-a652-fe437099830c",
  "docSlug": "dc4b6dd31d750eecf6a392f7e2ae4db2",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 22 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 22,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-9989-7672-a652-fe437099830c/15",
  "deckHref": "/decks/019de516-9989-7672-a652-fe437099830c",
  "deckJsonHref": "/decks/019de516-9989-7672-a652-fe437099830c.json",
  "deckAnchorHref": "/decks/019de516-9989-7672-a652-fe437099830c#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.23,
        "y": 0.22
      },
      "kind": "list",
      "text": "Second Wave\n7 Potential Approved Partner Programs\nLaunch Potential: 2025-2027\nSPL Programs: SPL Partner A Program 1, SPL Partner A Program 2, Caribou's CB-010, Editas' EDIT-301, Precision Bio's Azer-cel, Vor's Trem-cel, Invios' APN401\nIndications: Lymphoma/Leukemia, Solid Tumors, Sickle Cell Disease, Beta-Thalassemia",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03d3a0e7-9d0d-4d25-a0df-99fb9362c10a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.17,
        "x": 0.801,
        "y": 0.22
      },
      "kind": "list",
      "text": "Fifth Wave\nAdditional Licensed Programs and New Partnerships Signed\nLaunch Potential: 2032+",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06412a65-2f51-4fe2-a277-2f271ac3bee5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.43,
        "w": 0.19,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "First Wave\n1 Potential Approved Partner Program\nLaunch Potential: 2024\nSPL Program: Vertex's Exa-Cel\nIndications: Sickle Cell Disease, Beta-Thalassemia",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af4c7842-8acf-4521-af32-85619212f367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.19,
        "x": 0.61,
        "y": 0.22
      },
      "kind": "list",
      "text": "Fourth Wave\n20+ Additional Preclinical Partner Programs\nLaunch Potential: 2030+\nExample Indications: Solid Tumors, Autoimmune Diseases, Neurodegenerative Diseases, Genetic Diseases, Lymphoma/Leukemia",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd0d049d-4113-4356-98a4-f9db6e53cead",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.59,
        "w": 0.19,
        "x": 0.42,
        "y": 0.22
      },
      "kind": "list",
      "text": "Third Wave\n8 Potential Approved Partner Programs\nLaunch Potential: 2028-2030\nSPL Programs: Undisclosed\nExample Indications: Solid Tumors, Lymphoma/Leukemia, Multiple Myeloma, Sickle Cell Disease, Beta-Thalassemia",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f37e3a0c-7ea6-4ffc-b8d4-2369b722ac64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.16,
        "x": 0.08,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25848773-7f37-4093-a348-cc93953f91c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.89,
        "x": 0.039,
        "y": 0.049
      },
      "kind": "title",
      "text": "MaxCyte Partnerships - Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a108e7e3-ffab-4195-82ff-e288e1ff19e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "90d2488d-2453-4252-b2f4-4a50cb815e17",
      "evidence": "The roadmap on page 15 presents quick wins and big bets",
      "position": 1,
      "objective": "Show near and long-term revenue potential",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}